PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies

Institute builds upon institutional expertise to develop and advance impactful cell therapies for cancer, autoimmune conditions and infections

MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
2024-11-08
(Press-News.org) HOUSTON ― The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.

The institute will bring together top scientists and clinicians to lead exceptional discovery, translational and clinical research that will deliver new insights in immunology and cell engineering, fueling the creation of transformational new treatments that can be rapidly adapted to address emerging needs in cancer, autoimmune diseases, infections and other conditions. These efforts already have been catalyzed by philanthropic and institutional support of more than $80 million.

The institute will be led by Katy Rezvani, M.D., Ph.D., vice president & head of the Institute for Cell Therapy Discovery & Innovation. Rezvani also holds the inaugural Melvyn N. Klein Family Endowed Directorship for the Institute for Cell Therapy Discovery & Innovation.

“Cell therapies have delivered profound results for patients with hematologic cancers, but there remain too many patients that do not benefit. It is critical to our mission to bring these promising therapies forward as options for patients with cancer and other conditions,” Rezvani said. “Through our discoveries, we aim to provide many more patients with effective cell therapies that are available as off-the-shelf treatment options, limiting the need for lengthy hospital stays and associated costs.”

Cell therapies, often described as ‘living therapies,’ are sophisticated immunotherapy treatments that use immune cells from a patient or healthy donor as building blocks. Through specialized engineering and manufacturing techniques, researchers can enhance the ability of these cells to detect and eliminate cancer cells, infected cells or otherwise abnormal cells.

The institute will integrate across MD Anderson’s unique research ecosystem to accelerate the discovery and development of new cell therapies from preclinical studies through clinical trials. MD Anderson’s extensive scientific and clinical expertise, highlighted by the world’s largest cancer clinical trials program and premier research institutes – the James P. Allison Institute and Institute for Data Science in Oncology – will enable institute researchers to uncover new cell therapy targets and approaches. Collaborations with external researchers as well as biotechnology and pharmaceutical companies will further speed the pace of development.

“MD Anderson clinicians and researchers have been instrumental in shaping the cell therapy field, and we are proud to take this important step into the future,” said Peter WT Pisters, M.D., president of MD Anderson. “The Institute for Cell Therapy Discovery & Innovation is a key piece of our institutional strategy, as we focus on cancer breakthroughs to improve patient outcomes. Our world-class facilities, exceptional talent and unique research environment will enable our teams to deliver transformational new medicines and to further our efforts to maximize our impact on humanity to finally end cancer.”

Building on a robust research platform and previous discoveries

As leaders in cell therapy, MD Anderson researchers have an extensive history of cell therapy research and development in the preclinical and clinical setting. To date, the Food and Drug Administration (FDA) has approved six chimeric antigen receptor (CAR) T cell therapy products targeting CD19 and BCMA for B-cell lymphomas, leukemias and multiple myeloma, with several approvals based on clinical trials led by MD Anderson researchers.

MD Anderson also was the first to advance CAR natural killer (NK) cells into clinical studies for patients with lymphoid malignancies, based on cord blood-derived CD19 CAR NK cell therapies developed by Rezvani and her team.

Additional MD Anderson research has shown progress for new cell therapies in solid tumors, with numerous preclinical studies and clinical trials in progress. Some key published and presented research findings include:

Adoptive T cell receptor (TCR) therapy targeting MAGE-A4 achieved clinically significant results for patients with multiple solid tumor types in a Phase I trial Novel CD70-targeting CAR T cell therapy delivered promising early results in patients with metastatic clear cell renal cell carcinoma Engineered NK cells expressing interleukein-21 or missing the TFG-β receptor demonstrated strong antitumor activity against glioblastoma cells CAR NK cells expressing a second CAR molecule improved tumor specificity and enhanced NK cell activity Adding CD28 costimulation to CD70-targeting CAR NK cells enhanced antitumor activity and long-term cytotoxicity “For years, our talented scientists and clinicians have been at the forefront of discovery, understanding and development of novel cell therapies,” said Giulio Draetta, M.D., Ph.D., chief scientific officer at MD Anderson. “By integrating with experts across the research and clinical enterprise, the Institute for Cell Therapy Discovery & Innovation will be able to create important new treatments, tailored to unmet patient needs, in ways only possible here.”

Researchers at MD Anderson, home to the world’s largest cord blood bank, will continue to explore cord blood-derived NK cell therapies and investigate alternative sources, such as induced pluripotent stem cells (iPSCs), for NK cells, T cells, B cells and macrophages, all of which may be used for cell therapies. Researchers will investigate and identify additional targetable tumor antigens and immune signaling molecules, which play a key role in immune cells’ ability to eliminate tumor cells and reduce damage to healthy cells.

While cancer is a core focus of the institute, MD Anderson researchers’ extensive knowledge of cell biology and engineering also provides possibilities to develop cell therapies in autoimmune diseases and infections. Abnormal B cells can cause multiple autoimmune diseases, including Graves’ disease, rheumatoid arthritis and multiple sclerosis, and cell therapies could improve upon current steroid and immunosuppressive treatments.

Further, Rezvani’s team has successfully developed cell therapies that show promise in treating rare and often fatal brain infections as well as viral infections that can arise after stem cell transplants.

Bringing together top minds and the next generation of scientists

In addition to Rezvani’s leadership, clinical and research leaders at MD Anderson will come together to help manage and oversee the institute’s research efforts. An Internal Advisory Council will provide guidance and scientific input on the research projects, offering recommendations on new research proposals submitted to the institute. A Pipeline Review Committee will ensure research and development projects align with the institute’s overall strategic objectives.

The institute also established an Executive Advisory Board, comprised of top minds from around the world, to provide guidance and input on the work of the institute.

Recruitment and retention of top scientists in bioinformatics, cell therapy research and cell engineering are priorities to bolster research initiatives. In addition, supporting the research of young scientists with promising ideas is a key element of the institute’s work to advance cell therapies. The institute will establish a fellowship program to create an opportunity to mentor, recruit and educate the next generation of researchers.

More than $80 million in support funds advancement, accessibility of cell therapy

Philanthropic support from around the world will further fuel discovery, research and talent within the institute. To date, more than $80 million – over half of the institute’s fundraising goal – has been raised to aid in researchers’ investigation, development and manufacturing of next-generation cell therapies for cancer patients. Much of this support is directed to underwriting clinical trials that will accelerate treatments to the bedside.

“The unparalleled generosity of our dedicated donors has provided an incredible foundation for the institute, supporting the advancement and accessibility of cell therapies from the very beginning,” said Rezvani. “On behalf of our team and our patients, thank you for your foresight and confidence in science. Together, we will end cancer.”

The institute has received lead commitments from Meg and Kirk Gentle, Lindonlight Collective, The Marcus Foundation, Inc., The Margery L. Block Foundation, Melville Foundation and Tanoto Foundation and additional significant support from The James B. and Lois R. Archer Charitable Foundation, Ann and Clarence Cazalot, The Cockrell Foundation, The Cyvia & Melvyn Wolff Family Foundation; Vijay and Marie Goradia, Melvyn N. Klein, Marek Family Foundation, Gayle Stoffel, The McCombs Foundation, The Walters Family, and MD Anderson’s Accelerator Fund. These gifts and more provide a strong foundation for the institute today as fundraising continues toward a total goal of $150 million.

“We are grateful to the many donors who have supported our work in cell therapies for many years, particularly our generous lead and significant benefactors and our MD Anderson Cancer Center Board of Visitors members,” said Pisters. “Through their continued commitment to our mission, our hope is that the discoveries of today will sooner help more cancer patients, across more diseases and disease sites, putting us further on the path to Making Cancer History®.”

- 30 -

About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

© 2024 The University of Texas MD Anderson Cancer Center

END


[Attachments] See images for this press release:
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies 2

ELSE PRESS RELEASES FROM THIS DATE:

New quantum encoding methods slash circuit complexity in machine learning

New quantum encoding methods slash circuit complexity in machine learning
2024-11-08
A recent study by researchers from CSIRO and the University of Melbourne has made progress in quantum machine learning, a field aimed at achieving quantum advantage to outperform classical machine learning. Their work demonstrates that quantum circuits for data encoding in quantum machine learning can be greatly simplified without compromising accuracy or robustness. This research was published Sept.12 in Intelligent Computing, a Science Partner Journal. The team’s results, validated through both simulations and experiments on IBM quantum devices, show that their innovative encoding methods reduced circuit ...

New research promises an unprecedented look at how psychosocial stress affects military service members’ heart health

2024-11-08
A University of Massachusetts Amherst researcher will examine the role of cumulative psychosocial stress – as well as race, ethnicity and gender – among U.S. military personnel to gauge their impact on cardiovascular health and healthcare utilization. The study is funded with a $1 million grant from the Defense Health Agency, part of the Department of Defense (DoD). The findings will help the military develop programs for health promotion and health readiness for active duty and Reserve/National ...

Faster measurement of response to antibiotic treatment in sepsis patients using Dimeric HNL

2024-11-08
The biomarker human neutrophil lipocalin HNL, which was previously shown to be a useful indicator of bacterial infections, may also in the form of Dimeric HNL be used to effectively monitor the success of antibiotic treatment in sepsis. The first promising results in this regard were published in 2019 and now the research group has confirmed these results in a larger study. The study is published in the journal PLOS ONE. Sepsis, the costliest disease to health care, is a life-threatening condition with high mortality if not diagnosed and ...

Cleveland Clinic announces updated findings in preventive breast cancer vaccine study

Cleveland Clinic announces updated findings in preventive breast cancer vaccine study
2024-11-08
November 8, 2024, CLEVELAND: Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.   The study team found that the investigational vaccine was generally well tolerated and produced an immune response in most patients. The team described the side effects of the vaccine, showed the highest tolerated dose to date, and presented the immunologic effects of the vaccine. Findings are being presented at the Society for Immunotherapy of Cancer Annual Meeting.   Launched in 2021 and funded by the U.S. Department of Defense, the ongoing ...

Intergenerational effects of adversity on mind-body health: Pathways through the gut-brain axis

2024-11-08
The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Intergenerational Effects of Adversity on Mind-Body Health: Pathways Through the Gut-Brain Axis” on Tuesday, November 12, 2024, at 2:00 pm ET. The presenter, Bridget Laura Callaghan, Ph.D., is an Assistant Professor in the Department of Psychology at the University of California, Los Angeles (UCLA). At UCLA, Dr. Callaghan directs the Brain & Body Lab in the Department of Psychology and also heads the Mental Disorders and Pain research theme at the Goodman Luskin Microbiome Center. The webinar host, Jeffrey Borenstein, M.D., is the President ...

Watch this elephant turn a hose into a sophisticated showering tool

Watch this elephant turn a hose into a sophisticated showering tool
2024-11-08
Tool use isn’t unique to humans. Chimpanzees use sticks as tools. Dolphins, crows, and elephants are known for their tool-use abilities, too. Now a report in the Cell Press journal Current Biology on November 8, 2024, highlights elephants’ remarkable skill in using a hose as a flexible shower head. As an unexpected bonus, researchers say they also have evidence that a fellow elephant knows how to turn the water off, perhaps as a kind of “prank.” “Elephants are amazing with hoses,” says Michael Brecht ...

Chimpanzees perform better on challenging computer tasks when they have an audience

Chimpanzees perform better on challenging computer tasks when they have an audience
2024-11-08
When people have an audience watching them, it can change their performance for better or worse. Now, researchers reporting in the Cell Press journal iScience on November 8 have found that chimpanzees’ performance on computer tasks is influenced by the number of people watching them. The findings suggest that this “audience effect” predates the development of reputation-based human societies, the researchers say. “It was very surprising to find that chimpanzees are affected in their task performance by ...

New medical AI tool identifies more cases of long COVID from patient health records

2024-11-08
KEY TAKEAWAYS Researchers from Mass General Brigham are leveraging artificial intelligence to help identify the signs of long COVID, track how different symptoms manifest over time, and eliminate alternative explanations for patients’ symptoms. The new approach suggests that 22.8% of the population experience the symptoms of long COVID, a figure that may paint a more realistic picture of the pandemic’s long-term toll. Through analyzing a patient’s history over time, this new AI tool ...

Heat waves and adverse health events among dually eligible individuals 65 years and older

2024-11-08
About The Study: In this time-series study, heat waves were associated with increased adverse health events among dually eligible individuals 65 years and older. Without adaptation strategies to address the health-related impacts of heat, dually eligible individuals are increasingly likely to face adverse outcomes.  Corresponding Author: To contact the corresponding author, Hyunjee Kim, PhD, email kihy@ohsu.edu. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamahealthforum.2024.3884) Editor’s Note: Please ...

Catastrophic health expenditures for in-state and out-of-state abortion care

2024-11-08
About The Study: In this cross-sectional study of U.S. patients seeking abortion, many individuals and their households were estimated to incur catastrophic health expenditures, particularly those traveling from out of state. The financial and psychological burdens of abortion seeking have likely worsened after the Dobbs decision, as more people need to cross state lines to reach abortion care. The findings suggest expansion of insurance coverage to ensure equitable access to abortion care, irrespective of people’s state of residence, ...

LAST 30 PRESS RELEASES:

McCombs announces 2024 Hall of Fame inductees and rising stars

Stalling a disease that could annihilate banana production is a high-return investment in Colombia

Measurements from ‘lost’ Seaglider offer new insights into Antarctic ice melting

Grant to support new research to address alcohol-related partner violence among sexual minorities

Biodiversity change amidst disappearing human traditions

New approaches to synthesize compounds for pharmaceutical research

Cohesion through resilient democratic communities

UC Santa Cruz chemists discover new process to make biodiesel production easier, less energy intensive

MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies

New quantum encoding methods slash circuit complexity in machine learning

New research promises an unprecedented look at how psychosocial stress affects military service members’ heart health

Faster measurement of response to antibiotic treatment in sepsis patients using Dimeric HNL

Cleveland Clinic announces updated findings in preventive breast cancer vaccine study

Intergenerational effects of adversity on mind-body health: Pathways through the gut-brain axis

Watch this elephant turn a hose into a sophisticated showering tool

Chimpanzees perform better on challenging computer tasks when they have an audience

New medical AI tool identifies more cases of long COVID from patient health records

Heat waves and adverse health events among dually eligible individuals 65 years and older

Catastrophic health expenditures for in-state and out-of-state abortion care

State divorce laws, reproductive care policies, and pregnancy-associated homicide rates

Emerging roles of high-mobility group box-1 in liver disease

Exploring the systematic anticancer mechanism in selected medicinal plants

University of Cincinnati researchers pen editorial analyzing present, future of emergency consent in stroke trials

Scarlet Macaw parents ‘play favorites,’ purposefully neglect younger chicks

One gene provides diagnoses for 30 patients whose condition was unexplained for years

Current practice and emerging endoscopic technology in the diagnosis of colorectal cancer

Decoding 17-beta-hydroxysteroid dehydrogenase 13: A multifaceted perspective on its role in hepatic steatosis and associated disorders

Key pathway leading to neurodegeneration in early stages of ALS identified

Ferroptosis in regulating treatment tolerance of digestive system tumors

A promising future in pancreatic incidentaloma detection

[Press-News.org] MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
Institute builds upon institutional expertise to develop and advance impactful cell therapies for cancer, autoimmune conditions and infections